BIOMARIN PHARMACEUTICAL INC (BMRN)
BIOMARIN PHARMACEUTICAL INC (BMRN) from its SEC filings: 2025 revenue $3.2 billion (+13% vs the year before), net margin 11%, free cash flow $725.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $3.2 billion |
| Revenue growth | +13% |
| Net income | $348.9 million |
| Net margin | 10.8% |
| Free cash flow | $725.0 million |
| Diluted EPS | $1.80 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +20% |
| Cash | $874.0 million |
| Long-term debt | $3.5 billion |
| Share count, 1 year | +1% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.